Axsome Therapeutics (AXSM) | Stock Overview & Key Data
Axsome Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $117.58
High: $120.50
on August 22, 2025
52 Week Range
Low: $75.56
High: $139.13
on December 30, 2024
on February 21, 2025
All-Time High: $139.13 on February 17, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$5.8B
EPS
-5.06
P/E Ratio (TTM)
-19.85
Forward P/E
-54.23
P/B Ratio
79.85
PEG Ratio
0.47
Div. Yield
N/A
ROE
-280.69%
Beta
0.510
Debt to Equity
297.38
Financial Highlights
Profitability
Gross Margin
91.04%
Operating Margin
-29.87%
Profit Margin
-49.88%
Returns and Earnings
Return on Assets (TTM)
-21.90%
Return on Equity (TTM)
-280.69%
EBITDA
$-199.6M
Net Income (TTM)
$-246.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$10.17
Quarterly Revenue Growth (YoY)
72.10%
Quarterly Earnings Growth (YoY)
72.13%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Axsome Therapeutics AXSM | 5.85B Mid-cap | 8.52% | 15.56% | 13.57% | -9.34% | 35.72% | 34.69% | 76.54% | 55.50% |
| Vertex VRTX | 101.31B Large-cap | 0.59% | -15.96% | -8.96% | -17.97% | -2.62% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 63.57B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| BridgeBio Pharma BBIO | 9.58B Mid-cap | -4.36% | 7.23% | 48.86% | 35.39% | 74.04% | 93.92% | 368.32% | 65.87% |
| Madrigal MDGL | 9.07B Mid-cap | 12.12% | 32.32% | 51.70% | 28.73% | 32.16% | 64.07% | 491.89% | 288.86% |
| Halozyme HALO | 8.38B Mid-cap | 6.76% | 24.82% | 33.62% | 22.77% | 49.59% | 14.51% | 78.26% | 152.53% |
Ownership & Short Interest
Insider Ownership
16.09%
Institutional Ownership
77.24%
Shares Short
4M
Short Ratio
5.85
Short % of Shares Outstanding
8.78%
Average 10-Day Volume
490K
Average 90-Day Volume
621K
Axsome Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Axsome Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is AXSM's 52-week high and low?
- In the last 52 weeks, Axsome Therapeutics reached a high of $139.13 (on February 21, 2025) and a low of $75.56 (on December 30, 2024).
- What is the market cap and P/E ratio for AXSM?
- Curious about Axsome Therapeutics's size and valuation? Its market capitalization stands at 5.85B. When it comes to valuation, the P/E ratio (trailing twelve months) is -19.85, and the forward P/E (looking ahead) is -54.23.
- Does AXSM pay dividends? If so, what's the yield?
- As for dividends, Axsome Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Axsome Therapeutics's main competitors or similar companies to consider before investing?
When looking at Axsome Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX101.31B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN63.57B Healthcare Biotechnology -50.84% -1.12% BridgeBio Pharma
BBIO9.58B Healthcare Biotechnology 93.92% 368.32% Madrigal
MDGL9.07B Healthcare Biotechnology 64.07% 491.89% Halozyme
HALO8.38B Healthcare Biotechnology 14.51% 78.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Axsome Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Axsome Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -280.69%, the Debt to Equity ratio from the most recent quarter is 297.38, and its Gross Profit Margin stands at 91.04%.
- What is the recent revenue and earnings growth for AXSM?
- Looking at Axsome Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $495M. Compared to the same quarter last year (YoY), quarterly revenue grew by 72.10%, and quarterly earnings saw a YoY growth of 72.13%.
- How much of AXSM stock is held by insiders and institutions?
- Wondering who owns Axsome Therapeutics stock? Company insiders (like executives and directors) hold about 16.09% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 77.24%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.